FYI
The following may be of interest compiled from the latest Acadia update:
*1250 patients [25.0%] of the currently identified Retts patients in the US have been treated with Daybue.
*862 patients from the above group are currently being treated with Daybue leaving 388 patients [31.0%] no longer under treatment. This is a minimum drop- out rate as it includes all the new patients enrolled in the past 6 weeks.
*QI 2024 revenue was down 12.8% compared to Q4 2023 for a variety of subjective reasons.This is more than the revenue guidance miss suggests.
*According to Neuren gross to net discounting was higher in Q1 2024 than the previous quarter. No guide as to split between the Insured/Medicaid [discounted] patients has been indicated. Culper did not even mention discounting as a downside issue.
*Using the Q1 2024 revenue of $75.9M as a base Daybue sales have to increase in 9 months by between 21.9% and 38.3% off that base number to meet Acadias full year revenue guidance.
Kens
FYI The following may be of interest compiled from the latest...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.82 |
Change
-0.140(0.67%) |
Mkt cap ! $2.619B | |||
| Open | High | Low | Value | Volume |
| $21.00 | $21.21 | $20.31 | $12.98M | 630.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 166 | $20.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.82 | 371 | 11 |
View Market Depth
| Last trade - 15.43pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.75 |
Change
-0.140 ( 1.47 %) |
||||
| Open | High | Low | Volume | ||
| $20.97 | $21.15 | $20.32 | 197593 | ||
| Last updated 15.59pm 30/05/2024 ? | |||||
| NEU (ASX) Chart |